Sun Pharma gets US approval to sell generic Exelon
Sun Pharma gets US approval to sell generic Exelon
By Agencies
Sun Pharmaceutical Industries Ltd, India’s biggest drugmaker by market value, has got approval to sell its generic version of Novartis AG’s Exelon, in the US market with limited competition for six months, the drug maker said in a statement. Exelon is used to treat dementia.
The company has been allowed to sell capsules of rivastigmine tartrate, or generic Exelon, in four strengths. These dosages of Exelon have sales of about $200 million a year in the US, the company said.
Sun Pharma’s shares rose Rs27.80 , or 2.8%, to Rs1,007.50 on the Bombay Stock Exchange. The stock has gained 11% this year.
Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!